罗麦角林 | 107052-56-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 罗麦角林
• 英文名称: 6-methyl-9,10-didehydro-8β-(3,5-dioxopiperazine-1-yl-methyl)-ergoline
• 英文别名: PNU 160260；6-methyl-9,10-didehydro-8β-(3,5-dioxo-piperazin-1-yl-methyl)ergoline；6-methyl-9,10-didehydro-8β-(3,5-dioxo-piperazin-1-ylmethyl)-ergoline；romergoline；4-[[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]methyl]piperazine-2,6-dione
• CAS: 107052-56-2
• 化学式: C₂₀H₂₂N₄O₂
• 分子量: 350.42
• InChiKey: RJCXNCSJGRUWRW-SJKOYZFVSA-N

物化性质

• 沸点：
  629.7±55.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  68.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  罗麦角林 在 磺酰氯 、 三氟化硼乙醚 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以68%的产率得到8β-(3,5-dioxopiperazin-1-ylmethyl)-2-chloro-9,10-didehydro-6-methylergoline
  参考文献：
  名称：

  D1 Agonist and/or D2 antagonist dopamine receptor properties of a series of ergoline derivatives: a structure–activity study

  摘要：

  A series of (3,5-dioxopiperazin-1-yl)ergoline derivatives has been synthesised and evaluated in vitro and in vivo for their dopaminergic D-1 and D-2 components. The structural contributions to the pharmacological profile of the ergoline skeleton, its substituents on positions 1, 2, 6, 9, and the 3,5-dioxopiperazin-1-yl portion of the molecule were examined. Structure-activity relationships within this series suggested that substitution on the ergoline skeleton in position 1 or 2 and on the 3,5-dioxopiperazin-4-nitrogen generated compounds with a spectrum of dopamine agonistic/antagonistic activity sensitive to both the nature and position of substituents. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80045-2
• 作为产物：
  描述：

  N-<(9,10-didehydro-6-methylergolin-8β-yl)methyl>-iminodiacetamide 在 苯酚 作用下， 以63%的产率得到罗麦角林
  参考文献：
  名称：

  D1 Agonist and/or D2 antagonist dopamine receptor properties of a series of ergoline derivatives: a structure–activity study

  摘要：

  A series of (3,5-dioxopiperazin-1-yl)ergoline derivatives has been synthesised and evaluated in vitro and in vivo for their dopaminergic D-1 and D-2 components. The structural contributions to the pharmacological profile of the ergoline skeleton, its substituents on positions 1, 2, 6, 9, and the 3,5-dioxopiperazin-1-yl portion of the molecule were examined. Structure-activity relationships within this series suggested that substitution on the ergoline skeleton in position 1 or 2 and on the 3,5-dioxopiperazin-4-nitrogen generated compounds with a spectrum of dopamine agonistic/antagonistic activity sensitive to both the nature and position of substituents. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80045-2

文献信息

• [EN] CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS<br/>[FR] CONJUGUÉS DE COMPOSÉS HÉTÉROAROMATIQUES CONTENANT DE L'AZOTE
  申请人：ASCENDIS PHARMA AS

  公开号：WO2020254606A1

  公开（公告）日：2020-12-24

  The present invention relates to conjugates of ΤΓ-electron-pair-donating heteroaromatic nitrogen-comprising drugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said conjugates and the use of said conjugates as medicaments.

  本发明涉及ΤΓ-电子对供体杂芳氮含药物及其药用盐的结合物，包括所述结合物的药物组合物以及将所述结合物用作药物的用途。
• Piperazin-1-yl-ergoline derivatives, process for preparing them and pharmaceutical compositions containing them
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0197241A1

  公开（公告）日：1986-10-15

  Compounds I (R = H, CH3; R, = H, halogen, CH3, phenylthio, C, - C4 alkylthio; R2 = H, CH30 and R3 = H or R2 + R3 = chemical bond; R4 = C, - C4 hydrocarbon; R5, Rs, R8, R9 independently = H, C, - C4 alkyl or R5, R8 independently = H, C, - C4 alkyl and R6 + R9 = CH2CH7,CH2CH2CH2; R7 = H, C1 - C4 alkyl, phenyl, NR'R"; R', R" independently = H, C, - C4 alkyl, acyl or NR' R" = heterocyclic ring; W = 0, H2; n = O, 1, 2) and their pharmaceutically acceptable salts have antihypertensive activity and are useful anxiolytic and antipsychotic agents. A process for their preparation and pharmaceutical composition containing them are also described.

  化合物 I（R = H、CH3；R, = H、卤素、 、苯硫基、C、-C4 烷硫基；R2 = H、 0 和 R3 = H 或 R2 + R3 = 化学键；R4 = C、-C4 烃；R5、Rs、R8、R9 独立地 = H、C、-C4 烷基或 R5、R8 独立地 = H、C、-C4 烷基和 R6 + R9 = CH2CH7、CH2CH2CH2；R7 = H、C1 - C4 烷基、苯基、NR'R"；R'、R" 独立地 = H、C、- C4 烷基、酰基或 NR' R" = 杂环；W = 0、H2；n = O、1、2）及其药学上可接受的盐具有降压活性，是有用的抗焦虑和抗精神病药物。本文还描述了它们的制备过程和含有它们的药物组合物。
• Antiparkinson ergoline derivatives
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0317269A2

  公开（公告）日：1989-05-24

  Compounds of the formula I wherein R₁ represents a hydrogen atom or a methyl group, either R₂ and R₃ represent hydrogen atoms or together represent a chemical bond, R₄ represents a hydrogen atom or a C₁-C₄ alkyl group, R₅ represents a C₁-C₄ alkyl group or an allyl group and R₆ represents a hydrogen or halogen atom, and the pharmaceutically acceptable salt thereof, are useful for the manufacture of a pharmaceutical composition useful in the treatment of extrapyramidal syndromes such as Parkinson's disease.

  式 I 的化合物 其中 R₁ 代表氢原子或甲基，R₂ 和 R₃ 代表氢原子或一起代表化学键，R₄ 代表氢原子或 C₁-C₄ 烷基、R₅ 代表 C₁-C₄ 烷基或烯丙基，R₆ 代表氢原子或卤素原子，其药学上可接受的盐可用于制造治疗锥体外系综合征如帕金森病的药物组合物。
• Antiemesis ergoline derivatives
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0371246A1

  公开（公告）日：1990-06-06

  Compounds of the formula I wherein n is 1 or 2, R₁ represents a hydrogen atom or a C₁-C₄ alkyl group, R₂ represents a hydrogen atom and R₃ represents a hydrogen atom or a hydroxy group or R₂ and R₃ together represent a chemical bond, R₄ represents a hydrogen atom, or a phenyl or C₁-C₄ alkyl group, R₅ represents a C₁-C₄ alkyl group or an allyl group and R₆ represents a hydrogen or halogen atom, and the pharmaceutically acceptable salt thereof, are useful for the manufacture of a pharmaceutical composition useful in the treatment of emesis.

  式 I 的化合物 其中 n 为 1 或 2，R₁ 代表氢原子或 C₁-C₄ 烷基，R₂ 代表氢原子，R₃ 代表氢原子或羟基或 R₂ 和 R₃ 共同代表化学键，R₄ 代表氢原子、或苯基或 C₁-C₄烷基，R₅代表 C₁-C₄烷基或烯丙基，R₆代表氢原子或卤素原子，及其药学上可接受的盐，可用于制造治疗呃逆的药物组合物。
• Implants for the treatment of dopamine associated states
  申请人：NuPathe Inc.

  公开号：US10278916B2

  公开（公告）日：2019-05-07

  Biodegradable implants comprising dopamine modulating compounds are described.

  描述了包含多巴胺调节化合物的可生物降解植入物。